Analyst Research

Report Title Price
Provider: GlobalData
$125.00
Provider: Thomson Reuters Stock Report
$25.00
Provider: Wright Reports
$75.00
Provider: Reuters Investment Profile
$20.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Lupin Ltd Receives FDA Approval For Oral Contraceptive Vyfemla Tablets Generic Of Ovcon 35 Tablets


Friday, 27 Sep 2013 07:19am EDT 

Lupin Limited (Lupin), announced that it has received final approval for its Vyfemla Tablets (Norethindrone and Ethinyl Estradiol Tablets USP, 0.4mg/0.035 mg) from the United States Food and Drugs Administration (FDA) to market a generic version of Warner Chilcott Company, LLC.'s Ovcon 35 Tablets (Norethindrone and Ethinyl Estradiol Tablets USP, 0.4mg/0.035 mg). Lupin's US subsidiary Lupin Pharmaceuticals Inc. (LPI) shall commence marketing the product shortly. Lupin's Vyfemla Tablets (Norethindrone and Ethinyl Estradiol Tablets USP, 0.4 mg/0.035 mg) is the AB rated generic equivalent of Warner Chilcott's Ovcon 35 Tablets and is indicated for the prevention of pregnancy in women who elect to use this product as a method of contraception. 

Company Quote

1406.95
5.85 +0.42%
5:21am EST